Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03674424
Title Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

transitional cell carcinoma

Therapies

Avelumab + Gemcitabine + Paclitaxel

Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine

Avelumab

Avelumab + Cisplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries


No variant requirements are available.